Peking University　|　Chinese Version

  • Drug screening platform
  • Established in 1992, the innovative drug screening platform has completed screening research projects in the Eighth, Ninth and Tenth Five-Year Plan and is now undertaking the innovative drug screening research project in the Eleventh Five-Year Plan. At the present, the lab has established and improved the new drug screening platform, including sample bank, cell bank, screening information data set, cytology laboratory, molecular biology room and animal room, etc. The platform has established the screening methods and models for different types of drugs, including antineoplastic agent, cardiovascular drugs, anti-diabetic drugs, antiviral agents, antibacterial drugs and immunomodulator, etc, and can perform multi-screening for lead compounds. As high content screening system and automated high throughput drug screening robotic workstation was established during the period 2006~2010, the platform has reached the world advanced level and leading position in China. There are 18 full time staff members in the platform to perform screening work for drugs of major diseases.
  • The automated high throughput screening (HTS) robotic workstation (Catalyst Track System) is an advanced automation workstation system with the features of modularization, upgradeability and fast processing speed. Currently, the screening plat has more than 100 cellular models (including transgenic cells), which can be used in the HTS robotic workstation to perform at least 700, 000 times of sample screening, up to more than 2, 000, 000 times of sample screening.
  • High-content screening (HCS) is automated cell based screening, which uses fluorescent tags to label cells and conduct the multi-target screening while maintaining the structural and functional integrity of the cell. As the development of tumor diseases is a complicated multi-factor process, HCS can be used to conduct the multi-target test, which facilitates the discovery of active compounds. During the period 2006-2011, the lab developed and optimized analytical methods for different types of proteins, including tubulin, nuclear factor kB (NF-kB), tumor necrosis factor-a (TNF-a) and P-glycoprotein (P-gp), cell movement, membrane permeability and membrane potential, cell-cycle related protein, key proteins in signal communication system, proteasome and apoptosis related proteins.
  • At the present, the high-efficiency drug screening platform is capable of searching for lead compounds and promising candidate drugs with development value and independent intellectual property rights. The platform can provide drug screening technology services to research institutes and pharmaceutical companies for new drug research and development.
  • Contact person: CUI Jingrong
    Tel: 82802467
copyright 2014 State Key Laboratory Of Natural And Biomimetic Drugs, Peking University